Clinical trials: Chimeric Antigen Receptor T-cell Therapy
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells.
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
- Trial name
- NCT04033302
- Testing
- CD7-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Lymphoma
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.
- Trial name
- NCT07587840
- Testing
- CD22/CD19 CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Liping Dou
Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL)
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas
- Conditions
- Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory
- Trial name
- NCT07478848
- Testing
- Vancomycin 125mg, Radiation Therapy, CAR-T
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
AML
Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML
- Trial name
- NCT03585517
- Testing
- IM23
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Advanced Pancreatic Cancer
Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.
This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer.
- Trial name
- NCT07416240
- Testing
- Claudin18.2 Targeted Activated Dendritic Cells, Claudin18.2 Targeted CAR-T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hainan Cancer Hospital
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Study 18-255-01 was a Phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 versus placebo following CD19-directed CAR-T cell therapy in patients with R/R LBCL.
- Trial name
- NCT05664217
- Testing
- NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Nektar Therapeutics
Fatigue Symptom, Lymphoma Non-Hodgkin
Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
The incidence of cancer in 2023 is estimated at 433136 cases, according to INCa. Haemopathies account for 12% of these new cases of cancer cases of cancer, and around two-thirds are lymphoid haemopathies, in particular lymphomas.
- Conditions
- Fatigue Symptom, Lymphoma Non-Hodgkin, Chimeric Antigen Receptor T-cell Therapy, Adverse Events
- Trial name
- CAR-TIGUE (NCT06890091)
- Testing
- Fatigue assessment
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.
- Trial name
- NCT05155189
- Testing
- C-CAR031, Lenvatinib, Regorafenib (BAY 73-4506)
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
This study is an open-label, single-arm, prospective, multicenter, phase I/II clinical trial. It adopts the two-stage optimal design proposed by Bryant and Day to investigate the efficacy, safety, and in vivo pharmacokinetic…
- Trial name
- NCT07324889
- Testing
- CD19/BCMA CAR-T
- Volunteers
- 24 people
- Sponsor
- Yihao Wang
Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis
Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
This is an open-label, investigator-initiated clinical trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with refractory IIM and AAV.
- Trial name
- NCT06986018
- Testing
- RD06-04 Cell Injection Infusion
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in…
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NexCAR19 (NCT07502118)
- Testing
- Talikabtagene Autoleucel
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Health Institutes of Turkey
Autoimmune Diseases
CAR-T Cells Targeting Autoimmune Diseases
The purpose of this study is to assess the feasibility, safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.
- Trial name
- NCT05459870
- Testing
- 4SCAR T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Hepatocellular Carcinoma
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of GPC3-CAR-T cells in patients with hepatocellular carcinoma.
- Trial name
- NCT04506983
- Testing
- GPC3-CAR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute…
- Trial name
- NCT03854994
- Testing
- Anti-CD19 CAR-T Cells Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
B-Cell Acute Lymphoblastic Leukemia, Adult
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04788472
- Testing
- CAR-T cells targeting CD19 and CD22
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhejiang University
HCC
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
A Phase 1 Study of IL1RAP-targeting Chimeric Antigen Receptor T cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
- Trial name
- NCT06757881
- Testing
- Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai Zhongshan Hospital
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT04464200
- Testing
- 19(T2)28z1xx CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, B Cell
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma.
- Trial name
- NCT02992834
- Testing
- IL-2 pre-treated CD19 cells, IL-7/IL-15 pre-treated CD19 cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- jiangjingting
Large B-cell Lymphoma, Lymphoma
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy.
- Trial name
- NCT05464719
- Testing
- Loncastuximab Tesirine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Plasma Cell Leukemia
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
- Trial name
- NCT05822037
- Testing
- CT0594CP
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The First Affiliated Hospital of Soochow University